ProCE Banner Activity

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer: OS Analysis From a Randomized Phase II Trial

Slideset Download
Conference Coverage
Addition of the GR modulator relacorilant to nab-paclitaxel numerically improved OS vs nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer.

Released: June 15, 2022

Expiration: June 14, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab